ethyl-8-(2-fluorobenzyl)imidazo[1,5-a]pyrimidine-6-carboxylate | 1011528-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-8-(2-fluorobenzyl)imidazo[1,5-a]pyrimidine-6-carboxylate
• 英文别名: Ethyl 8-(2-fluorobenzyl)imidazo[1,5-a]pyrimidine-6-carboxylate；ethyl 8-[(2-fluorophenyl)methyl]imidazo[1,5-a]pyrimidine-6-carboxylate
• CAS: 1011528-07-6
• 化学式: C₁₆H₁₄FN₃O₂
• 分子量: 299.304
• InChiKey: XGZVSBVRKNCTNU-UHFFFAOYSA-N

物化性质

• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl-8-(2-fluorobenzyl)imidazo[1,5-a]pyrimidine-6-carboxylate 在 氨 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 3.33h， 生成 8-(2-fluorobenzyl)imidazo[1,5-a]pyrimidine-6-carbonitrile
  参考文献：
  名称：

  Substituted annellated pyrimidines and use thereof

  摘要：

  本申请涉及新型取代的螺合嘧啶类化合物，其生产方法，单独或组合使用用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物产品的用途，特别是用于治疗和/或预防心血管疾病。

  公开号：

  US20130338137A1
• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醚 、 乙醇 、 水 为溶剂， 生成 ethyl-8-(2-fluorobenzyl)imidazo[1,5-a]pyrimidine-6-carboxylate
  参考文献：
  名称：

  Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

  摘要：

  The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.

  DOI：

  10.1021/acs.jmedchem.7b00449

文献信息

• PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS
  申请人：Schirok Hartmut

  公开号：US20100029653A1

  公开（公告）日：2010-02-04

  The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型氮杂双环化合物，其制备方法，它们单独或与其他物质结合用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders
  申请人：Bayer Intellectual Property GmbH

  公开号：US08309551B2

  公开（公告）日：2012-11-13

  The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型杂环双环化合物、其制备过程，它们单独或组合使用用于治疗和/或预防疾病，以及它们用于制造治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• SUBSTITUIERTE ANNELLIERTE PYRIMIDINE UND IHRE VERWENDUNG
  申请人：Bayer Intellectual Property GmbH

  公开号：EP2751106B1

  公开（公告）日：2017-10-18
• US8309551B2
  申请人：——

  公开号：US8309551B2

  公开（公告）日：2012-11-13
• US8859569B2
  申请人：——

  公开号：US8859569B2

  公开（公告）日：2014-10-14